Compare AbbVie Inc (ABBV) vs Cipher Mining Inc (CIFR) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

CIFR trades at $21.73, up 8.43% today but remains in a bearish technical trend. The company is transitioning from Bitcoin mining to AI data center operations, with $11.4B in contracted lease revenue from AWS and Fluidstack. Despite strong analyst support (13 buy ratings), fundamentals show deep losses with -427.79% net margin and negative cash flow from operations.

The investment case hinges on successful execution of the AI infrastructure pivot, with revenue expected to ramp from 2027. Key risks include high valuation multiples, negative profitability, and execution challenges in data center deployment. The consensus price target of $31.61 suggests 45% upside if the transition succeeds.